Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls. First-line bortezomib (Velcade) appears to ...

Bortezomib (Velcade, Janssen‑Cilag) is an anticancer drug that works by reversible proteasome inhibition. By inhibiting proteasomes (multi-enzyme complexes present in all cells), bortezomib interferes ...

In this report, the effects of a combined treatment with the proteasome inhibitor bortezomib and either a recombinant adeno-associated virus type 2 (rAAV-2)-mediated p53 gene transfer or ...

Learn everything you need to know about Bortezomib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Please provide your email address to receive an email when new articles are posted on . The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young ...

NOTE. A total of eight patients, four in each study group, could not be evaluated for adverse events because they did not receive a study drug because of withdrawal of consent (three patients in the ...

Bortezomib (Velcade, Millennium Pharmaceuticals) recently had its approval extended to cover use in patients with newly diagnosed mantle cell lymphoma on the basis of data from a phase 3 clinical ...

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of bortezomib, having considered evidence on the nature of the condition and the value placed on the ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...

Recently, on the basis of a case series involving six patients, Sykes et al. 1 described the TEMPI syndrome, a novel multisystem disease defined by telangiectasias, erythrocytosis with elevated ...